MiMedx Group, Inc. (NASDAQ:MDXG) went up to recover about 277.89% since recording its record low price of $0.95. The stock experienced -4.01% slump, arriving at $3.59 on 3/19/2019. During the day, the stock price traveled from $3.59 to $3.98. This company shares are 415.32% off its target price of $18.5 and the current market capitalization stands at $398.62M. The recent change has given its price a 28.73% lead over SMA 50 and -64.06% deficit over its 52-week high. The stock witnessed 25.09% gains, 131.61% gains and -27.33% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MDXG’s volatility during a week at 8.6% and during a month it has been found around 5.35%.MiMedx Group, Inc. (MDXG) Top Holders
Institutional investors currently hold around $32 million or 70.08% in MDXG stock. Look at its top three institutional owners: Marshall Wace, Llp owns $13.23 million in MiMedx Group, Inc., which represents roughly 3.32% of the company’s market cap and approximately 41.35% of the institutional ownership. Similar statistics are true for the second largest owner, Manufacturers Life Insurance Company, The, which owns 1,424,447 shares of the stock are valued at $5.33 million. The third largest holder is Disciplined Growth Investors Inc /Mn, which currently holds $1.81 million worth of this stock and that ownership represents nearly 0.45% of its market capitalization.
At the end of December reporting period, 15 institutional holders increased their position in MiMedx Group, Inc. (NASDAQ:MDXG) by some 5,412,193 shares, 171 decreased positions by 73,618,209 and 10 held positions by -70,345,145. That puts total institutional holdings at 8,685,257 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 3,987,609 shares while 158 institutional investors sold out their entire positions totaling 71,261,947 shares.
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry.